Imbrium Therapeutics

Imbrium Therapeutics is a biopharmaceutical company in the clinical development stage that is dedicated to advancing medical science by creating new treatments for cancer, pain, and central nervous system disorders. Established in 2019 as a subsidiary of Purdue Pharma, Imbrium has a specific focus on cancer, CNS, and non-opioid pain therapies, and is committed to rapidly advancing the development of differentiated therapeutic agents. NIMIUM Therapeutics is a start-up in the life-sciences sector based in Montreal, concentrated on developing an innovative therapy to counteract the negative effects of excessive caloric intake and promote healthy aging. The research is centered on the discovery of glycerol-3-phosphate phosphatase (G3PP), an enzyme crucial in glucose, lipid, and energy metabolism in humans, which contributes to the development of cardiometabolic diseases (CMD), type 2 diabetes, obesity, and related health disorders.